Yoshida M - Search Results

1

A reduction of epidermal growth factor receptor is involved in brefelamide-induced inhibition of phosphorylation of ERK in human astrocytoma cells.

Honma S, Saito M, Kikuchi H, Saito Y, Oshima Y, Nakahata N, Yoshida M. Honma S, et al. Among authors: yoshida m. Eur J Pharmacol. 2009 Aug 15;616(1-3):38-42. doi: 10.1016/j.ejphar.2009.06.030. Epub 2009 Jun 23. Eur J Pharmacol. 2009. PMID: 19559020

2

Dual effect of saikogenin D: in vitro inhibition of prostaglandin E2 production and elevation of intracellular free Ca2+ concentration in C6 rat glioma cells.

Kodama Y, Xiaochuan L, Tsuchiya C, Ohizumi Y, Yoshida M, Nakahata N. Kodama Y, et al. Among authors: yoshida m. Planta Med. 2003 Aug;69(8):765-7. doi: 10.1055/s-2003-42795. Planta Med. 2003. PMID: 14531029

3

Involvement of reactive oxygen species and stress-activated MAPKs in satratoxin H-induced apoptosis.

Nusuetrong P, Yoshida M, Tanitsu MA, Kikuchi H, Mizugaki M, Shimazu K, Pengsuparp T, Meksuriyen D, Oshima Y, Nakahata N. Nusuetrong P, et al. Among authors: yoshida m. Eur J Pharmacol. 2005 Jan 10;507(1-3):239-46. doi: 10.1016/j.ejphar.2004.11.046. Epub 2004 Dec 19. Eur J Pharmacol. 2005. PMID: 15659314

4

Participation of epoxygenase activation in saikogenin D-induced inhibition of prostaglandin E(2) synthesis.

Toriniwa Y, Lv X, Kodama Y, Ohizumi Y, Yoshida M, Nakahata N. Toriniwa Y, et al. Among authors: yoshida m. J Pharm Pharmacol. 2006 Jun;58(6):859-66. doi: 10.1211/jpp.58.6.0017. J Pharm Pharmacol. 2006. PMID: 16734988

5

Distinct effects of z-335, a new thromboxane A2 receptor antagonist, on rabbit platelets and aortic smooth muscle.

Yoshida M, Sato Y, Shimura T, Ohkubo S, Honma S, Tanaka T, Kurimoto T, Nakahata N. Yoshida M, et al. Pharmacology. 2007;79(1):50-6. doi: 10.1159/000097632. Epub 2006 Nov 30. Pharmacology. 2007. PMID: 17139194

6

Satratoxin H generates reactive oxygen species and lipid peroxides in PC12 cells.

Nusuetrong P, Pengsuparp T, Meksuriyen D, Tanitsu M, Kikuchi H, Mizugaki M, Shimazu K, Oshima Y, Nakahata N, Yoshida M. Nusuetrong P, et al. Among authors: yoshida m. Biol Pharm Bull. 2008 Jun;31(6):1115-20. doi: 10.1248/bpb.31.1115. Biol Pharm Bull. 2008. PMID: 18520041 Free article.

7

Interleukin-6 plays a protective role in development of cisplatin-induced acute renal failure through upregulation of anti-oxidative stress factors.

Mitazaki S, Honma S, Suto M, Kato N, Hiraiwa K, Yoshida M, Abe S. Mitazaki S, et al. Among authors: yoshida m. Life Sci. 2011 Jun 20;88(25-26):1142-8. doi: 10.1016/j.lfs.2011.04.016. Epub 2011 May 4. Life Sci. 2011. PMID: 21570986

8

Interleukin-6 modulates oxidative stress produced during the development of cisplatin nephrotoxicity.

Mitazaki S, Hashimoto M, Matsuhashi Y, Honma S, Suto M, Kato N, Nakagawasai O, Tan-No K, Hiraiwa K, Yoshida M, Abe S. Mitazaki S, et al. Among authors: yoshida m. Life Sci. 2013 Apr 9;92(12):694-700. doi: 10.1016/j.lfs.2013.01.026. Epub 2013 Feb 4. Life Sci. 2013. PMID: 23384965

9

Amelioration of cisplatin-induced mouse renal lesions by a cyclooxygenase (COX)-2 selective inhibitor.

Honma S, Takahashi N, Shinohara M, Nakamura K, Mitazaki S, Abe S, Yoshida M. Honma S, et al. Among authors: yoshida m. Eur J Pharmacol. 2013 Sep 5;715(1-3):181-8. doi: 10.1016/j.ejphar.2013.05.023. Epub 2013 Jun 4. Eur J Pharmacol. 2013. PMID: 23747596

10

Regeneration of injured renal tubules.

Yoshida M, Honma S. Yoshida M, et al. J Pharmacol Sci. 2014;124(2):117-22. doi: 10.1254/jphs.13r12cp. Epub 2014 Jan 25. J Pharmacol Sci. 2014. PMID: 24463777 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,151 results

Search Page

Filters